drugset / Trial / NCT01950481
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | 750 mg | Oral |
Indications
No indication recorded.